NasdaqGS:SNDXBiotechs
A Look At Syndax Pharmaceuticals (SNDX) Valuation After Strong Revenue Growth And Multiple FDA Approvals
Syndax Pharmaceuticals (SNDX) is back in focus after reporting fourth quarter and full year 2025 results, highlighting sharp revenue growth tied to recently approved cancer therapies Revuforj and Niktimvo, as well as its expanding commercial footprint.
See our latest analysis for Syndax Pharmaceuticals.
The earnings release, third FDA approval within a year, conference appearance, and fresh shelf registration have all landed against a backdrop where the 1 year total shareholder return of...